Edwards Lifesciences Corp Stock Price, News & Analysis

Edwards Lifesciences reported Q1 2021 financial results with sales of $1.2 billion, an 8% year-over-year increase. Diluted EPS was $0.54, surpassing expectations. Notable TAVR sales reached $792 million, growing 7%. The company received approval for pivotal trials in TAVR for moderate AS patients and low surgical risk patients in Japan. Adjusted EPS guidance for 2021 has been raised to $2.07 to $2.27. Despite expected near-term COVID impacts, Edwards forecasts robust growth in structural heart procedures, with a projected global TAVR market exceeding $7 billion by 2024.

Edwards Lifesciences (NYSE: EW) is set to announce its operating results for the quarter ending March 31, 2021, after market close on April 20, 2021. A conference call will be held at 5:30 p.m. ET that day to discuss these results. Investors can participate by calling (877) 704-2848 or (201) 389-0893. An audio replay will be accessible for 72 hours post-call. The call will also be available via a live or archived webcast on their Investor Relations website.

Edwards Lifesciences (NYSE: EW) announced positive outcomes from the COMMENCE clinical trial, showcasing its bioprosthetic surgical aortic valve with the RESILIA tissue platform. Data presented at the Society of Thoracic Surgeons meeting indicate excellent safety and hemodynamic performance over five years, with no instances of structural valve deterioration. The study involved 689 patients and marked a significant advancement in valve technology, focusing on durability for active patients. Edwards continues research to validate long-term performance and is committed to enhancing patient care.

Edwards Lifesciences reported Q4 2020 earnings, with sales at $1.2 billion, a 1% increase. TAVR sales rose 2% to $776 million. Adjusted EPS grew 2% to $0.50, while full-year sales reached $4.4 billion, up 1%. However, U.S. TAVR sales declined mid-single digits due to COVID impacts. The company expects 2021 sales growth of 15-20%, with a long-term TAVR opportunity exceeding $7 billion by 2024. Despite some declines in Surgical Structural Heart and Critical Care segments, R&D expenditures increased, focusing on transcatheter innovations.

Edwards Lifesciences (NYSE: EW) will announce its operating results for Q4 2020, ending December 31, 2020, after market close on January 27, 2021. A conference call will follow at 5:00 p.m. ET to discuss the results. Interested participants can join by dialing (877) 704-2848 or (201) 389-0893. An audio replay will be accessible for 72 hours post-call. Edwards Lifesciences is recognized for innovations in structural heart disease and critical care monitoring, aiming to enhance patient care through collaboration with healthcare professionals.

Edwards Lifesciences (NYSE: EW) has initiated the RESTORE clinical trial with the first patient treated for severe degenerative mitral valve regurgitation using the investigational HARPOON Beating Heart Mitral Valve Repair System. This innovative device employs a less invasive technique compared to traditional open-heart surgery, potentially improving recovery for patients. The trial will enroll up to 360 patients across the U.S. and Canada, aiming to establish the device's safety and effectiveness. Edwards also emphasizes its commitment to advancing patient-focused cardiac solutions.

At its annual investor conference on December 10, 2020, Edwards Lifesciences discussed its long-term growth strategy and provided 2021 financial guidance. The company projects global sales between $4.9 and $5.3 billion, with TAVR sales expected between $3.2 and $3.6 billion, reflecting a 15-20% growth rate. Adjusted earnings per share are projected at $2.00 to $2.20. Despite COVID-19 challenges, Edwards anticipates strong growth in TAVR and new product launches across its structural heart portfolio.

Edwards Lifesciences reported Q3 2020 sales of $1.1 billion, a 4% increase from the previous year, with a strong performance in TAVR, which grew 6% to $745 million. Adjusted EPS rose 9% to $0.51, prompting an increase in full-year EPS guidance to $1.85-$1.95. The company noted significant growth potential in TMTT therapies, with $12 million in sales. Overall gross margin was 75.5%. The fourth quarter outlook suggests similar growth to Q3, and the company anticipates double-digit growth in TAVR sales for 2021.

Edwards Lifesciences is set to announce its operating results for the quarter ending September 30, 2020, after market close on October 21, 2020. A conference call to discuss these results will take place at 5:00 p.m. ET on the same day. Participants can join the call by dialing (877) 704-2848 or (201) 389-0893. An audio replay will be available for 72 hours post-call. Further details can be accessed on the company's Investor Relations website.